Andere talen EXOPHARM

Aandelen

EX1

AU0000030975

Beurs gesloten - Australian S.E. Andere beurzen 02:10:45 02-10-2023			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0275 ^AUD	+10,00%		-.--%	-.--%

01/05	Tryp Therapeutics Inc. (CNSX:TRYP) heeft de overname van Exopharm Limited (ASX:EX1) afgerond in een omgekeerde fusietransactie.	CI
26/02	Exopharm Limited rapporteert resultaten voor het halfjaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tryp Therapeutics Inc. completed the acquisition of Exopharm Limited in a reverse merger transaction.	01/05
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02
Exopharm to Cut CEO Role Amid Cost Reductions	28/11
Exopharm Limited Announces Ian Dixon's Employment as CEO Expects to End in Early Calendar Year 2024	27/11
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29-08-23
Exopharm Limited Announces Executive Changes	22-06-23
Exopharm Achieves Initial Success With Exosome Products; Shares Fall 21%	28-04-23
Exopharm Secures R&D Cash Loan Advance from Radium Capital	09-03-23
Exopharm Limited announced that it has received AUD 1 million in funding	09-03-23
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26-02-23
Exopharm Limited Announces Board Changes	22-02-23
Exopharm Limited announced that it expects to receive AUD 0.6 million in funding	13-02-23
Exopharm Limited Announces Resignation of Elizabeth McGregor as Non-Executive Director	20-12-22
Sartorius BIA Separations and Exopharm Ltd Testing the Synergy of Exopharm's Patented LEAP Technology Together with Bia's Unique Cim (Convective Interaction Media) Monolith Chromatography for Improved Large- Scale Exosome Production and Commercialization	16-11-22
Exopharm Limited Will Commence LEAP Technology Transfer to AIRM under MSA	13-11-22
Exopharm Receives $2.6 Million R&D Tax Rebate	27-10-22
Exopharm Says Drug Product Safe After Animal Testing	28-09-22
Exopharm Limited Announces Study Results Indicate Exosomes Safe for Clinical Pursuit	28-09-22
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31-08-22
Exopharm Limited Auditor Raises 'Going Concern' Doubt	30-08-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen EXOPHARM

Aandelen

EX1

AU0000030975

Andere talen

Filters